CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Neurovax

vaccine brand

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionMay 29, 2025
Entity authorityQ7002774 ↗
Source-derived summary

Neurovax is a vaccine designed to treat patients with multiple sclerosis. Developed by Immune Response BioPharma, Inc. it is currently in phase II clinical trials. Neurovax is designed to stimulate FOXP3+ regulatory T-cells that can then suppress the autoreactive T-cells in some patients.

Development

The development program for Neurovax terminated in 2008, when the company developing this vaccine was filed for bankruptcy. All work with Neurovax is now being developed by Immune Response BioPharma, Inc. Granted U.S. Patent 8,053,197 Methods for Treating Auto-Immune Diseases and has licensed TCR FOXP3+ Technology from OHSU in December 2011.

Editorial summary

The public source identifies “Neurovax” as vaccine brand. This brief keeps that definition visible, then builds a research path around Neurovax, vaccine and brand.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current lead gives the account dated anchors—2008, 2011—that can be checked directly. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Neurovax, vaccine and brand providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Neurovax”, the useful work is to connect “vaccine brand” to the records capable of establishing context and consequence.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 29, 2025. The linked authority identifier is Q7002774. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2008 and 2011.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Neurovax”, its source revision and the description used here.
  2. Expand the search: follow Neurovax primary sources, Neurovax archive and Neurovax research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Neurovax”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Neurovax” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.